相关实验视频
Updated: Jan 11, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.3K
在阿尔茨海默氏症早期,胆酸概况和白质微观结构变化在阿尔茨海默氏症早期
Ye Mo1, Yifeng Peng2,
1Department of Neurology, Southern University of Science and Technology Hospital, Shenzhen 518000, China.
Brain research bulletin
|November 16, 2025
概括
周围胆汁酸概况,特别是GDCA/TDCA比率,与阿尔茨海默氏症早期白质变化相关. 这些发现表明,肠道干预可能是阿尔茨海默病 (AD) 治疗的未来战略.
科学领域:
- 神经科学是一个神经科学.
- 胃肠病学 胃肠病学
- 生物化学 生物化学
背景情况:
- 目前的阿尔茨海默病 (AD) 治疗提供有限的长期益处.
- 新兴研究将改变的肠肝胆酸 (BA) 代谢与AD病理联系起来.
- 这项研究研究了外围BA特征与前进性AD早期白质变化之间的关系.
研究的目的:
- 为了确定外围胆汁酸 (BA) 形状是否与白质微观结构的变化相关,在患有无记忆性轻度认知障碍 (MCI) 的人群中.
- 探索BA新陈代谢作为早期阿尔茨海默病 (AD) 治疗点的潜力.
主要方法:
- 利用来自阿尔茨海默病神经成像计划的127名参与者的数据 (46名对照,81名MCI).
- 测量了33个胆酸 (BA) 和3个BA比的血清度,以及脑脊液生物标志物.
- 分析了扩散张力MRI指标 (FA,MD,RD,AxD),使用基于通道的空间统计和基于图谱的感兴趣区域.
主要成果:
- 特定的BA配置文件,如较高的taurochenodeoxycholic acid和较低的apocholic acid,与增加的分数异性质 (FA) 有关.
- 轴向扩散率 (AxD),平均扩散率 (MD) 和辐射扩散率 (RD) 的升高与降低的脱酸和改变的BA比率 (GLCA/CDCA) 相相关.
- 甘氨酸与氨酸 (GDCA/TDCA) 的比率显示出最强的关联,在关键白质道中广泛扩散性增加和减少FA.
结论:
- 外围BA概况,特别是肠道衍生的GDCA/TDCA比率,反映了白质变性在遗忘性MCI中.
- 肝脏-微生物BA代谢中断被认为是前进性AD的可改变因素.
- 针对BA的肠道干预措施代表了未来AD疾病修饰策略的有希望的途径.
更多相关视频
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
11.1K
08:25Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
Published on: April 19, 2021
3.9K
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782